Synthetic organic

InformationAvitinib (AC0010) Avitinib (AC0010) is a pyrrolopyrimidine-based irreversible EGFR inhibitor that is mutation-selective with IC50 value of 0.18 nM against EGFR L858R/T790M double mutations, nearly 43-fold greater potency over wild-type

InformationAvitinib (AC0010) Avitinib (AC0010) is a pyrrolopyrimidine-based irreversible EGFR inhibitor that is mutation-selective with IC50 value of 0.18 nM against EGFR L858R/T790M double mutations, nearly 43-fold greater potency over wild-type

InformationAvitinib (AC0010) Avitinib (AC0010) is a pyrrolopyrimidine-based irreversible EGFR inhibitor that is mutation-selective with IC50 value of 0.18 nM against EGFR L858R/T790M double mutations, nearly 43-fold greater potency over wild-type

InformationAvitinib (AC0010) Avitinib (AC0010) is a pyrrolopyrimidine-based irreversible EGFR inhibitor that is mutation-selective with IC50 value of 0.18 nM against EGFR L858R/T790M double mutations, nearly 43-fold greater potency over wild-type

InformationAvitinib (AC0010) Avitinib (AC0010) is a pyrrolopyrimidine-based irreversible EGFR inhibitor that is mutation-selective with IC50 value of 0.18 nM against EGFR L858R/T790M double mutations, nearly 43-fold greater potency over wild-type

avitriptan.

avitriptan.

AVL-292 is a covalent, orally active, and highly selective BTK inhibitor with IC50 of &lt:0.5 nM, displaying at least 1400-fold selectivity over the other kinases assayed. Phase 1.

AVL-292 is a covalent, orally active, and highly selective BTK inhibitor with IC50 of &lt:0.5 nM, displaying at least 1400-fold selectivity over the other kinases assayed. Phase 1.

AVL-292 is a covalent, orally active, and highly selective BTK inhibitor with IC50 of &lt:0.5 nM, displaying at least 1400-fold selectivity over the other kinases assayed. Phase 1.

AVL-292 is a covalent, orally active, and highly selective BTK inhibitor with IC50 of &lt:0.5 nM, displaying at least 1400-fold selectivity over the other kinases assayed. Phase 1.

avoralstat.